retatrutide trial data Retatrutide just delivered the first top-line Phase 3 results for a triple agonist in obesity — and the findings from TRIUMPH-4 are striking👇

Retatrutide just delivered the most powerful weight loss data ever recorded in a Phase 3 obesity trial. At 104 weeks, participants on the 12 mg dose lost an average of 85 pounds

26.76

★★★★☆4.8 (126)

NEW Data drop at #ADA2023: Retatrutide, a triple agonist (GLP1, GIP, glucagon) lost an incredible 24.2% of their body weight, which amounts to 58 lbs! This data suggests retatrutide is the most

25.29

★★★★★4.9 (98)

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

20.81

★★★★★5.0 (157)

Here we go! The first phase 3 trial for Retatrutide in obesity Here's how it compares to the other drugs with phase 3 data I used the treatment-regimen estimand, which measures weight

24.72

★★★★★4.7 (84)

Everyone's talking about Retatrutide… but what does the actual data say? Here's a breakdown based on published clinical trials: • 24.2% body weight loss (48 weeks) • 86% liver fat reduction (small

22.76

★★★★★4.9 (203)

Retatrutide Weight Loss Treatment Explained

27.89

★★★★★5.0 (176)

The numbers from Lilly's Phase 3 retatrutide trial dropped this week and I haven't been able to stop thinking about them. Not only as a doctor but as a long-term GLP-1 user

22.73

★★★★★4.8 (132)